Medicare's new GLP-1 Bridge covers Wegovy, Zepbound KwikPen, and Foundayo for a $50 monthly copay through December 2027 for eligible Part D members.
The Medicare GLP-1 Bridge is a temporary CMS demonstration that, from July 1, 2026 through December 31, 2027, lets eligible Part D members fill the FDA-approved weight-loss drugs Wegovy, Zepbound KwikPen, or Foundayo for a flat $50 monthly copay if they meet BMI and qualifying-condition criteria.
For the first time, Medicare is helping cover GLP-1 medications prescribed purely for weight loss. On July 1, 2026, the Centers for Medicare and Medicaid Services (CMS) launched the Medicare GLP-1 Bridge, a temporary demonstration running through December 31, 2027. Here is what the program covers, who qualifies, and exactly where each drug stands with the FDA.
CMS, through its Innovation Center, opened a demonstration that gives eligible Medicare Part D members a flat $50 monthly copay for select GLP-1 medications used for weight management. GLP-1 drugs are glucagon-like peptide-1 receptor agonists: they mimic a gut hormone that curbs appetite and slows digestion.
The Bridge covers all formulations of Wegovy and Foundayo, plus the KwikPen formulation of Zepbound. It runs outside the normal Part D benefit, so a plan does not have to opt in and the $50 copay does not count toward a member's deductible or out-of-pocket maximum. Manufacturers Novo Nordisk and Eli Lilly agreed to supply the drugs at a roughly $245 net monthly price. Eligibility is tiered by body mass index: BMI 35 or higher on its own, BMI 30 or higher with a qualifying condition, or BMI 27 or higher with a qualifying condition such as prediabetes or established cardiovascular disease. A prescriber must attest that the member meets the criteria.
Every drug in the Bridge is FDA-approved for chronic weight management. Wegovy (semaglutide, Novo Nordisk) is FDA-approved for chronic weight management, and all of its formulations are covered. Zepbound (tirzepatide, Eli Lilly) is FDA-approved for chronic weight management, but only its KwikPen formulation is included in the Bridge. Foundayo (orforglipron, Eli Lilly) is FDA-approved as of April 2026 for chronic weight management and is the first oral, small-molecule GLP-1 pill for obesity; it can be taken at any time of day without food or water restrictions. None of these are experimental or compounded within this program: coverage here applies to their approved weight-management use.
Medicare has long been barred by statute from covering drugs used strictly for weight loss, so many older adults have paid list prices that can top $1,000 a month or gone without. The Bridge is a workaround built as a time-limited demonstration, not a permanent benefit, and it narrows a longstanding gap between what commercial insurance and Medicare would pay. Importantly, it is not open to everyone: members who already receive a GLP-1 through Part D for an approved condition such as type 2 diabetes, sleep apnea, or MASH are not eligible for the Bridge, because their drug is already covered through the standard benefit.
The demonstration is scheduled to end on December 31, 2027 unless CMS extends or replaces it, and it sits alongside a separate, broader effort known as the BALANCE model whose Medicare Part D piece was delayed. Whether the Bridge becomes durable policy will depend on cost, uptake, and future rulemaking. Coverage details, participating plans, and the exact qualifying conditions can shift, so members should confirm specifics with their Part D plan and prescriber rather than assume eligibility. injector.world reports these changes as they happen and does not recommend starting or stopping any medication.